文献速递乳腺技术与安全CTMR

疑似转移性乳腺癌中对比增强CT、双层探测器光谱CT与全身MRI比较:一项前瞻性诊断准确性研究

Comparison of contrast-enhanced CT, dual-layer detector spectral CT, and whole-body MRI in suspected metastatic breast cancer: a prospective diagnostic accuracy study.
PubMed 文献 · Eur Radiol · 2021-05-18

182例活检证实乳腺癌且疑似转移的患者前瞻性接受对比增强双层探测器光谱CT与全身MRI检查,分别由两组放射科医生盲法判读。按病灶分析,光谱CT的AUC(0.84)显著高于CT(0.80,p=0.001)和全身MRI(0.82,p=0.02),敏感度0.75分别高于CT的0.66(p<0.0001)和全身MRI的0.65(p=0.002);按患者分析,光谱CT和全身MRI的AUC均显著高于CT,且全身MRI特异度显著高于CT和光谱CT。

要点

  • 按病灶分析,光谱CT的AUC 0.84显著高于CT的0.80(p=0.001)和全身MRI的0.82(p=0.02)。
  • 光谱CT敏感度0.75显著高于CT的0.66(p<0.0001)和全身MRI的0.65(p=0.002)。
  • 按患者分析,全身MRI特异度0.96显著高于CT的0.84(p=0.001)和光谱CT的0.87(p=0.02)。

核心结论

  • 光谱CT按病灶诊断性能和敏感度显著高于CT和全身MRI;按患者分析,光谱CT与全身MRI诊断性能相当且均优于CT。

研究设计与样本

  • 前瞻性诊断准确性研究,纳入182例活检证实乳腺癌且疑似转移的患者,均接受对比增强双层探测器光谱CT和全身MRI。

诊断标准与关键数值

  • 按病灶AUC:CT 0.80、光谱CT 0.84、全身MRI 0.82;光谱CT显著高于CT(p=0.001)和全身MRI(p=0.02)。
  • 按病灶敏感度与特异度:CT 0.66和0.94、光谱CT 0.75和0.95、全身MRI 0.65和0.98;光谱CT敏感度显著高于CT(p<0.0001)和全身MRI(p=0.002)。
  • 按患者AUC:CT 0.85、光谱CT 0.90、全身MRI 0.92;光谱CT和全身MRI均显著高于CT(p=0.04和p=0.03)。
  • 按患者敏感度:光谱CT 0.89 vs CT 0.79,光谱CT显著增高(p=0.04)。
  • 按患者特异度:全身MRI 0.96 vs CT 0.84(p=0.001),全身MRI 0.96 vs 光谱CT 0.87(p=0.02),全身MRI显著更高。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To compare diagnostic accuracy of contrast-enhanced CT, dual-layer detector spectral CT (DL-CT), and whole-body MRI (WB-MRI) for diagnosing metastatic breast cancer.

METHODS: One hundred eighty-two biopsy-verified breast cancer patients suspected of metastatic disease prospectively underwent contrast-enhanced DL-CT and WB-MRI. Two radiologists read the CT examinations with and without spectral data in consensus with 3-month washout between readings. Two other radiologists read the WB-MRI examinations in consensus. Lymph nodes, visceral lesions, and bone lesions were assessed. Readers were blinded to other test results. Reference standard was histopathology, previous or follow-up imaging, and clinical follow-up.

RESULTS: Per-lesion AUC was 0.80, 0.84, and 0.82 (CT, DL-CT, and WB-MRI, respectively). DL-CT showed significantly higher AUC than CT (p = 0.001) and WB-MRI (p = 0.02). Sensitivity and specificity of CT, DL-CT, and WB-MRI were 0.66 and 0.94, 0.75 and 0.95, and 0.65 and 0.98, respectively. DL-CT significantly improved sensitivity compared to CT (p < 0.0001) and WB-MRI (p = 0.002). Per-patient AUC was 0.85, 0.90, and 0.92 (CT, DL-CT, and WB-MRI, respectively). DL-CT and WB-MRI had significantly higher AUC than CT (p = 0.04 and p = 0.03). DL-CT significantly increased sensitivity compared to CT (0.89 vs. 0.79, p = 0.04). WB-MRI had significantly higher specificity than CT (0.84 vs. 0.96, p = 0.001) and DL-CT (0.87 vs. 0.96, p = 0.02).

CONCLUSIONS: DL-CT showed significantly higher per-lesion diagnostic performance and sensitivity than CT and WB-MRI. On a per-patient basis, DL-CT and WB-MRI had equal diagnostic performance superior to CT.

KEY POINTS: • Spectral CT has higher diagnostic performance for diagnosing breast cancer metastases compared to conventional CT and whole-body MRI on a per-lesion basis. • Spectral CT and whole-body MRI are superior to conventional CT for diagnosing patients with metastatic breast cancer. • Whole-body MRI is superior to conventional CT and spectral CT for diagnosing bone metastases.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Buus TW, Rasmussen F, Nellemann HM, et al. Comparison of contrast-enhanced CT, dual-layer detector spectral CT, and whole-body MRI in suspected metastatic breast cancer: a prospective diagnostic accuracy study. Eur Radiol. 2021. PMID: 34008104. doi:10.1007/s00330-021-08041-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。